Schematic overview of the cellular and molecular mechanisms involved in the cancer progression, including the proposed cellular and molecular mechanisms in cancer cells trajectory. AT1: alveolar type 1 cells; AT2: alveolar type 2 cells; AAH: atypical adenomatous hyperplasia; AIS: adenocarcinoma in situ; MIA: minimally invasive adenocarcinoma; IA: invasive adenocarcinoma; EMT: epithelial-mesenchymal transition

Home

Download

Statistics

Help

Contact

	Gene summary
	Malignant transformation analysis
	Malignant transformation related pathway analysis
	Cell-cell communication analysis
	Single-cell gene regulatory network inference analysis
	Somatic mutation of malignant transformation related genes
	Related drugs of malignant transformation related genes

Gene: RNF168

Gene summary for RNF168

Gene summary.

Gene information	Species	Human
	Gene symbol	RNF168
	Gene ID	165918
	Gene name	ring finger protein 168
	Gene Alias	RIDL
	Cytomap	3q29
	Gene Type	protein-coding
	GO ID	GO:0000209
	UniProtAcc	Q8IYW5

Top

Malignant transformation analysis

Identification of the aberrant gene expression in precancerous and cancerous lesions by comparing the gene expression of stem-like cells in diseased tissues with normal stem cells

Malignant transformation involving gene list.

Entrez ID	Symbol	Replicates	Species	Organ	Tissue	Adj P-value	Log2FC	Malignancy
165918	RNF168	CCI_1	Human	Cervix	CC	2.66e-08	9.86e-01	0.528
165918	RNF168	CCI_2	Human	Cervix	CC	1.46e-11	1.42e+00	0.5249
165918	RNF168	CCI_3	Human	Cervix	CC	1.49e-08	9.66e-01	0.516
165918	RNF168	sample3	Human	Cervix	CC	4.18e-08	2.49e-01	0.1387
165918	RNF168	T1	Human	Cervix	CC	1.29e-05	3.93e-01	0.0918
165918	RNF168	T3	Human	Cervix	CC	1.96e-08	2.75e-01	0.1389
165918	RNF168	LZE2T	Human	Esophagus	ESCC	1.67e-06	9.48e-01	0.082
165918	RNF168	LZE4T	Human	Esophagus	ESCC	1.75e-31	1.08e+00	0.0811
165918	RNF168	LZE7T	Human	Esophagus	ESCC	1.07e-16	9.32e-01	0.0667
165918	RNF168	LZE8T	Human	Esophagus	ESCC	4.89e-18	2.48e-01	0.067
165918	RNF168	LZE20T	Human	Esophagus	ESCC	3.72e-02	1.52e-01	0.0662
165918	RNF168	LZE21D1	Human	Esophagus	HGIN	4.61e-06	1.21e+00	0.0632
165918	RNF168	LZE22T	Human	Esophagus	ESCC	3.21e-02	6.18e-01	0.068
165918	RNF168	LZE24T	Human	Esophagus	ESCC	6.57e-12	4.68e-01	0.0596
165918	RNF168	LZE21T	Human	Esophagus	ESCC	3.61e-22	1.30e+00	0.0655
165918	RNF168	LZE6T	Human	Esophagus	ESCC	8.05e-07	2.35e-01	0.0845
165918	RNF168	P1T-E	Human	Esophagus	ESCC	2.21e-11	8.36e-01	0.0875
165918	RNF168	P2T-E	Human	Esophagus	ESCC	8.34e-48	1.03e+00	0.1177
165918	RNF168	P4T-E	Human	Esophagus	ESCC	1.81e-51	1.33e+00	0.1323
165918	RNF168	P5T-E	Human	Esophagus	ESCC	1.81e-39	8.54e-01	0.1327

Page: 1 2 3 4 5 6

Transcriptomic changes along malignancy continuum.

Tissue	Expression Dynamics	Abbreviation
Cervix		CC: Cervix cancer
		HSIL_HPV: HPV-infected high-grade squamous intraepithelial lesions
		N_HPV: HPV-infected normal cervix
Esophagus		ESCC: Esophageal squamous cell carcinoma
		HGIN: High-grade intraepithelial neoplasias
		LGIN: Low-grade intraepithelial neoplasias
Liver		HCC: Hepatocellular carcinoma
		NAFLD: Non-alcoholic fatty liver disease
Oral Cavity		EOLP: Erosive Oral lichen planus
		LP: leukoplakia
		NEOLP: Non-erosive oral lichen planus
		OSCC: Oral squamous cell carcinoma
Skin		AK: Actinic keratosis
		cSCC: Cutaneous squamous cell carcinoma
		SCCIS:squamous cell carcinoma in situ
Thyroid		ATC: Anaplastic thyroid cancer
		HT: Hashimoto's thyroiditis
		PTC: Papillary thyroid cancer

∗log2FC in expression of this searched gene in stem-like cells from each diseased tissue sample relative to stem-like cells in normal samples in each tissue plotted against the malignancy continuum. Samples are colored based on if they are from different disease stage.

Top

Malignant transformation related pathway analysis

Find out the enriched GO biological processes and KEGG pathways involved in transition from healthy to precancer to cancer

Figure of enriched GO biological processes.

Tissue	Disease Stage	Enriched GO biological Processes
Colorectum	AD
Colorectum	SER
Colorectum	MSS
Colorectum	MSI-H
Colorectum	FAP

∗Top 15 enriched GO BP terms are showed in the bar plot of each disease state in each tissue. Each row represents a significant GO biological process which is colored according to the -log10(p.adjust).

Page: 1 2 3 4 5 6 7 8 9

Enriched GO biological processes.

GO ID	Tissue	Disease Stage	Description	Gene Ratio	Bg Ratio	pvalue	p.adjust	Count
GO:00002097	Cervix	CC	protein polyubiquitination	58/2311	236/18723	1.57e-07	7.41e-06	58
GO:00093149	Cervix	CC	response to radiation	86/2311	456/18723	3.50e-05	5.63e-04	86
GO:00165705	Cervix	CC	histone modification	84/2311	463/18723	1.70e-04	2.01e-03	84
GO:20010209	Cervix	CC	regulation of response to DNA damage stimulus	46/2311	219/18723	1.92e-04	2.23e-03	46
GO:00102126	Cervix	CC	response to ionizing radiation	34/2311	148/18723	2.23e-04	2.53e-03	34
GO:00510528	Cervix	CC	regulation of DNA metabolic process	65/2311	359/18723	9.25e-04	7.84e-03	65
GO:00024603	Cervix	CC	adaptive immune response based on somatic recombination of immune receptors built from immunoglobulin superfamily domains	62/2311	356/18723	3.09e-03	2.03e-02	62
GO:00063684	Cervix	CC	transcription elongation from RNA polymerase II promoter	17/2311	69/18723	3.65e-03	2.33e-02	17
GO:0002263	Cervix	CC	cell activation involved in immune response	50/2311	279/18723	4.16e-03	2.57e-02	50
GO:0002443	Cervix	CC	leukocyte mediated immunity	73/2311	440/18723	5.01e-03	2.98e-02	73
GO:00063545	Cervix	CC	DNA-templated transcription, elongation	20/2311	91/18723	6.88e-03	3.74e-02	20
GO:00705343	Cervix	CC	protein K63-linked ubiquitination	14/2311	56/18723	6.93e-03	3.74e-02	14
GO:00023813	Cervix	CC	immunoglobulin production involved in immunoglobulin-mediated immune response	16/2311	70/18723	1.01e-02	4.91e-02	16
GO:000020916	Esophagus	HGIN	protein polyubiquitination	58/2587	236/18723	6.29e-06	1.97e-04	58
GO:00063687	Esophagus	HGIN	transcription elongation from RNA polymerase II promoter	24/2587	69/18723	8.93e-06	2.64e-04	24
GO:005105214	Esophagus	HGIN	regulation of DNA metabolic process	79/2587	359/18723	1.38e-05	3.85e-04	79
GO:200102019	Esophagus	HGIN	regulation of response to DNA damage stimulus	52/2587	219/18723	5.00e-05	1.19e-03	52
GO:00063548	Esophagus	HGIN	DNA-templated transcription, elongation	27/2587	91/18723	6.62e-05	1.52e-03	27
GO:005105416	Esophagus	HGIN	positive regulation of DNA metabolic process	47/2587	201/18723	1.65e-04	3.21e-03	47
GO:00165708	Esophagus	HGIN	histone modification	92/2587	463/18723	1.70e-04	3.30e-03	92

Page: 1 2 3 4 5 6 7 8 9 10 11

Enriched KEGG pathways.

Pathway ID

Tissue

Disease Stage

Description

Gene Ratio

Bg Ratio

pvalue

p.adjust

qvalue

Count

Page: 1

Top

Cell-cell communication analysis

Identification of potential cell-cell interactions between two cell types and their ligand-receptor pairs for different disease states

Ligand

Receptor

LRpair

Pathway

Tissue

Disease Stage

Page: 1

Top

Single-cell gene regulatory network inference analysis

Find out the significant the regulons (TFs) and the target genes of each regulon across cell types for different disease states

Cell Type

Tissue

Disease Stage

Target Gene

RSS

Regulon Activity

∗The dot plots of a searched regulon are shown for all cell subpopulations in each disease state of each tissue based on the regulon specific score inferred using pySCENIC and by calculating the average expression.

Page: 1

Top

Somatic mutation of malignant transformation related genes

Annotation of somatic variants for genes involved in malignant transformation

Hugo Symbol

Variant Class

Variant Classification

dbSNP RS

HGVSc

HGVSp

HGVSp Short

SWISSPROT

BIOTYPE

SIFT

PolyPhen

Tumor Sample Barcode

Tissue

Histology

Sex

Age

Stage

Therapy Types

Drugs

Outcome

RNF168

SNV

Missense_Mutation

novel

c.947N>A

p.Thr316Lys

p.T316K

Q8IYW5

protein_coding

tolerated(0.31)

benign(0.015)

TCGA-AO-A128-01

Breast

breast invasive carcinoma

Female

<65

I/II

Chemotherapy

doxorubicin

RNF168

SNV

Missense_Mutation

c.527N>G

p.Glu176Gly

p.E176G

Q8IYW5

protein_coding

deleterious(0)

probably_damaging(0.961)

TCGA-D8-A1XQ-01

Breast

breast invasive carcinoma

Female

>=65

I/II

Unknown

RNF168

SNV

Missense_Mutation

c.1220N>C

p.Arg407Thr

p.R407T

Q8IYW5

protein_coding

deleterious(0)

possibly_damaging(0.84)

TCGA-D8-A27G-01

Breast

breast invasive carcinoma

Female

>=65

I/II

Unknown

RNF168

SNV

Missense_Mutation

c.1049N>C

p.Arg350Thr

p.R350T

Q8IYW5

protein_coding

tolerated(0.14)

benign(0)

TCGA-D8-A27G-01

Breast

breast invasive carcinoma

Female

>=65

I/II

Unknown

RNF168

SNV

Missense_Mutation

c.812N>C

p.Ile271Thr

p.I271T

Q8IYW5

protein_coding

tolerated(0.59)

benign(0.038)

TCGA-E9-A1RG-01

Breast

breast invasive carcinoma

Female

<65

III/IV

Hormone Therapy

tamoxiphen

RNF168

insertion

Frame_Shift_Ins

novel

c.113_114insAGGATCTCGCTCCGTCCTCCAGGCTGGA

p.Cys39GlyfsTer62

p.C39Gfs*62

Q8IYW5

protein_coding

TCGA-A8-A07R-01

Breast

breast invasive carcinoma

Female

>=65

III/IV

Ancillary

zoledronic

RNF168

insertion

Nonsense_Mutation

novel

c.574_575insCCTCAGGATTTCCAGTTTTCTCAAAGTGAACCATTGGATT

p.Gly192AlafsTer10

p.G192Afs*10

Q8IYW5

protein_coding

TCGA-AO-A0JB-01

Breast

breast invasive carcinoma

Female

<65

III/IV

Chemotherapy

cyclophosphamide

RNF168

SNV

Missense_Mutation

c.1531N>C

p.Glu511Gln

p.E511Q

Q8IYW5

protein_coding

tolerated(0.28)

benign(0)

TCGA-DS-A1OC-01

Cervix

cervical & endocervical cancer

Female

<65

I/II

Chemotherapy

gemcitabine

RNF168

SNV

Missense_Mutation

c.1531G>C

p.Glu511Gln

p.E511Q

Q8IYW5

protein_coding

tolerated(0.28)

benign(0)

TCGA-IR-A3LA-01

Cervix

cervical & endocervical cancer

Female

<65

I/II

Chemotherapy

cisplatin

RNF168

SNV

Missense_Mutation

rs766109423

c.584N>T

p.Ser195Leu

p.S195L

Q8IYW5

protein_coding

tolerated(1)

benign(0)

TCGA-JW-A5VL-01

Cervix

cervical & endocervical cancer

Female

<65

I/II

Unknown

Page: 1 2 3 4 5 6 7

Top

Related drugs of malignant transformation related genes

Identification of chemicals and drugs interact with genes involved in malignant transfromation

(DGIdb 4.0)

Entrez ID

Symbol

Category

Interaction Types

Drug Claim Name

Drug Name

PMIDs

Page: 1